Delving into the Latest Updates on Erenumab (Genetical Recombination) with Synapse

Many people with migraine also experience tinnitus - a persistent ringing, buzzing, or hissing in the ears - and research suggests these conditions share underlying biological mechanisms, including a protein called calcitonin gene-related peptide (CGRP) that is active in both the brain and the inner ear. COMPACT-PM is a randomized trial comparing two classes of migraine preventive medications in adults with bothersome tinnitus and a history of migraine: anti-CGRP therapies (newer injectable or oral agents that block CGRP or its receptor) versus conventional migraine preventives (antidepressants including amitriptyline, nortriptyline, and venlafaxine; antihypertensives including propranolol, verapamil, and candesartan; and the anticonvulsant topiramate). Participants are randomly assigned - like a coin flip - to one of the two treatment groups; neither group receives a placebo, as both receive active migraine treatment. The study's primary outcome is change in the Tinnitus Functional Index (TFI) over 24 weeks, with additional measures including hearing tests, balance assessments, auditory brainstem response testing, and a comprehensive symptom diary. The study is conducted at the Stanford Ear Institute and is funded by a philanthropic gift to the Department of Otolaryngology - Head & Neck Surgery at Stanford University.

Start Date01 Jul 2026

Sponsor / Collaborator

Stanford University

NCT06237062

/ TerminatedNot Applicable

Real-world Experience of Patients Newly Started on Erenumab in the Gulf Region: a Longitudinal Prospective Observational Study

The objective of this study was to evaluate the effect of erenumab on medication-specific treatment satisfaction in patients who newly started on erenumab over 12 weeks

Start Date05 Jun 2024

Sponsor / Collaborator

Novartis Pharmaceuticals Canada, Inc.

NCT06212661

/ Enrolling by invitationNot ApplicableIIT

Migraine Medication Effects on Urinary Symptoms

A prospective observational cohort trial to study the effects of CGRP inhibitors (CGRPi) on lower urinary tract symptoms (LUTS) and bladder/pelvic pain. Candidates for either CGRPi or an alternative therapy for refractory migraines (OnabotulinumtoxinA (BoNTA) extracranial muscle injections) with baseline LUTS will be recruited. The investigators will assess LUTS and pelvic pain using validated symptom and quality-of-life questionnaires, pretreatment and at 3 months post-treatment follow-up, comparing change in symptoms based on treatment received.

Start Date05 Apr 2024

Sponsor / Collaborator

The Cleveland Clinic Foundation

100 Clinical Results associated with Erenumab (Genetical Recombination)

Login to view more data

100 Translational Medicine associated with Erenumab (Genetical Recombination)

Login to view more data

100 Patents (Medical) associated with Erenumab (Genetical Recombination)

Login to view more data

642

Literatures (Medical) associated with Erenumab (Genetical Recombination)

01 Nov 2026·AMERICAN JOURNAL OF OPHTHALMOLOGY

Epidemiology, Safety of Dilation, and Medication-Associated Risk of Acute Angle-Closure Crisis in the United States

Article

Author: Schultz, Jeffrey S ; Shah, Jainam ; Adamovich-Zeitlin, Richard ; Oseni, Jessinta ; Shrivastava, Anurag ; Berdahl, John P ; Ong, Joshua ; Pathuri, Sachin

OBJECTIVE:

To evaluate the epidemiology of acute angle-closure crisis (AACC), the safety of pharmacologic dilation, and medication-associated AACC risk in the United States.

DESIGN:

Retrospective clinical cohort study.

SUBJECTS:

Adults (≥18 years) in a multicenter federated electronic health record network.

METHODS:

Using deidentified electronic medical record data from 2010 to 2025, AACC cases were identified using ICD-10-CM codes followed by definitive therapeutic intervention within 14 days. Incidence, prevalence, and diagnostic trends were evaluated with Mann-Kendall tests. Dilation-associated AACC risk was assessed among patients undergoing dilation-associated ophthalmic examinations, with incident AACC identified within 14 days (with 24-hour sensitivity analysis). Medication-associated AACC risk was evaluated using active-comparator cohorts with 1:1 propensity score matching and Cox proportional hazards models over a 30-day window.

MAIN OUTCOME MEASURES:

AACC incidence (per 100,000 dilation-associated examinations) and hazard ratios (HRs) with 95% confidence intervals (CIs) for medication-associated AACC risk.

RESULTS:

From 2010 to 2025, the cumulative incidence of AACC was 0.014%, and the prevalence of primary angle-closure glaucoma (PACG) among patients with AACC was 16.7%. AACC incidence and the prevalence of PACG among patients with AACC increased over time (all P < .001). Gonioscopy utilization declined, whereas anterior segment imaging increased (all P < .001). Across 3,400,372 dilation-associated examinations among 2,444,570 patients, post-dilation AACC was rare (3.1 per 100,000; 95% CI: 2.3-3.7), with similar findings in a 24-hour sensitivity analysis; events concentrated among patients with anatomical risk factors. Increased AACC risk was observed for medications with established associations and some with less established associations, including lactulose (HR: 1.67), metoclopramide (1.38), sumatriptan (1.64), prazosin (1.32), and terazosin (1.77) (all P < .05). Previously unreported associations were observed for calcitonin gene-related peptide (CGRP) monoclonal antibodies (erenumab [1.33]), calcium channel blockers (CCBs) (verapamil [1.89], diltiazem [1.74]), and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (alirocumab [1.54], evolocumab [1.46]) (all P < .05).

CONCLUSIONS:

AACC following pharmacologic dilation was rare and occurred predominantly among anatomically predisposed patients, supporting the safety of dilation in routine care. Medication-associated risk signals highlight the importance of proactive ocular risk assessment and medication reconciliation. Novel associations with CCBs, CGRP monoclonal antibodies, and PCSK9 inhibitors warrant further investigation.

01 Sep 2026·PHARMACOECONOMICS

Cost-Utility Analysis of Calcitonin Gene-Related Peptide Monoclonal Antibodies for Patients with Episodic Migraine Headache in the USA

Article

Author: Bounthavong, Mark ; Dong, Ariel Weiming

OBJECTIVE:

We aimed to evaluate the cost effectiveness of eptinezumab and erenumab as a preventive treatment of migraine in patients with episodic migraine with different routes of administration, from the US healthcare payer perspective.

METHODS:

A hybrid decision tree-Markov model was constructed to assess the cost effectiveness of eptinezumab and erenumab as a preventive treatment for migraines compared to topiramate among patients with episodic migraine from the US healthcare payer's perspective. A decision tree model simulated the probability of patients experiencing adequate responses to treatments in the first 6 months, which fed into a Markov model using a 2-year time horizon. The Markov model consisted of three states: "Off Preventive Treatment," "Preventive Treatment," and death. Total costs, quality-adjusted life-years, and incremental cost-effectiveness ratios were estimated for each strategy followed by sensitivity analyses. An annual discount rate of 3% was applied to both costs and utility values, and costs were reported in 2025 US dollars.

RESULTS:

In the base-case results, total costs of eptinezumab and erenumab were $21,767 and $21,739, respectively. Total quality-adjusted life-years for eptinezumab and erenumab were 1.32 and 1.30, respectively. Base-case incremental cost-effectiveness ratios of eptinezumab and erenumab compared to topiramate were $117,626 and $155,259 per quality-adjusted life-year gained, respectively. Erenumab was eliminated because of extended dominance; thus, eptinezumab was selected for additional sensitivity analyses. In the one-way sensitivity analysis, treatment response, utility values, and drug costs were influential in changing the study's conclusions. In the probabilistic sensitivity analysis, eptinezumab was cost effective in 1.8%, 33.6%, and 78.6% of simulations when the willingness-to-pay threshold was $50,000, $100,000, and $150,000 per quality-adjusted life-year gained, respectively.

CONCLUSIONS:

Our analysis suggests that eptinezumab might be cost effective at a willingness-to-pay threshold of $150,000 per quality-adjusted life-year gained compared with topiramate, with uncertainties on health state utilities and pharmaceutical costs. Policymakers should carefully consider the tradeoffs between costs and benefits when making decisions regarding formulary coverage for the episodic migraine population.

01 Sep 2026·Patient-Patient Centered Outcomes Research

Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants

Article

Author: Matsumori, Yasuhiko ; Takeshima, Takao ; Sanno, Naoko ; Dias-Barbosa, Carla ; Doi, Hikaru ; Igarashi, Hisaka ; Duenas, Ashley ; Tatsuoka, Yoshihisa ; Hasebe, Miki ; Kitamura, Shigekazu ; Hareendran, Asha ; Tanaka, Shigeya ; Nagamitsu, Tsutomu

BACKGROUND:

In Japan, migraine is estimated to affect 6-8.6% of the population, and the burden of migraine and barriers to migraine care are substantial. Although new preventive treatments are available for migraine, there is limited qualitative information about the lived experience of adults with migraine in Japan and how these treatments improve their day-to-day lives.

METHODS:

Participants in a qualitative interview study embedded in a phase 3 randomized, double-blind, placebo-controlled clinical trial (NCT03812224) were invited to take part in a telephone interview after completing 24 weeks of double-blind treatment with once-monthly erenumab 70 mg and a subsequent 28-week open-label treatment period. Interviews were conducted by Japanese interviewers using a semi-structured interview guide. The interviews were audio-recorded, transcribed, and qualitatively analysed using a thematic content analysis approach.

RESULTS:

Forty-one participants were interviewed between May and September 2020. The mean age of participants was 43.8 years; 82.9% were female, 51.2% had episodic migraine, and 48.8% had chronic migraine. Prior to trial participation, patients identified pain, nausea, and profound tiredness-often expressed as a "lack of energy" or feeling "exhausted" or "drained"-as the most bothersome symptoms. Patients also emphasized difficulties concentrating, interference with school, work, and household responsibilities, and emotional strain as the most bothersome impacts of living with migraine. At the end of the trial, patients reported important improvements in their migraine experience-such as reductions in migraine frequency, severity, and duration-which translated into tangible benefits in daily life. Overall, satisfaction with erenumab was high (mean score 6.8 on a 0-10 scale) and was mainly driven by the reduced frequency and duration of migraine.

CONCLUSION:

Results from this qualitative study confirm that migraine significantly impacts the quality of life of adults in Japan. This study provides valuable insights into patients' experiences of erenumab, which reduced the frequency, severity, or duration of migraine episodes in most patients, resulting in better functioning and overall quality of life.

TRIAL REGISTRATION:

Clinicaltrials.gov NCT03812224. Registered January 23, 2019.

69

News (Medical) associated with Erenumab (Genetical Recombination)

10 Sep 2026

·allsci.com

AbbVie's atogepant meets primary endpoint in Phase III menstrual migraine trial

Atogepant (Qulipta/Aquipta) met the primary endpoint and all eight ranked secondary endpoints in the Phase III LUNA trial evaluating preventive treatment of menstrual migraine, AbbVie (NYSE: ABBV) reported. No treatment is currently approved specifically for menstrual migraine, meaning the data could support a dedicated menstrual-migraine indication. The LUNA study is a Phase III, multicenter, randomized, double-blind, placebo-controlled trial that enrolled 468 adult women with pure menstrual migraine or menstrually-related migraine across sites in Europe and Asia. The dosing regimen differed from atogepant's approved once-daily preventive use: participants took the drug for seven consecutive days starting three days before the onset of menses, repeated over three menstrual cycles. The primary endpoint was the change from baseline in migraine days during the perimenstrual period, averaged across those three cycles. Atogepant produced a mean reduction of 1.20 migraine days versus 0.40 days with placebo — a difference of 0.80 days (p<0.0001). All eight ranked secondary endpoints, covering headache burden, acute medication use, functional disability, cognitive function, and responder rates, also reached statistical significance (p<0.0001). Safety was consistent with atogepant's established profile, with no new signals identified. Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP from binding to its receptor, interrupting a signaling pathway elevated during migraine attacks. The drug is already approved in the US for both episodic and chronic migraine prevention under the brand name Qulipta, and in June 2026 received European Commission approval for the acute treatment of migraine in adults as Aquipta — its second EU indication. The LUNA data extend atogepant into a distinct patient subpopulation that existing CGRP-targeted therapies have not been specifically studied in or approved for. Anti-CGRP monoclonal antibodies such as Amgen's Aimovig (erenumab) and Eli Lilly's Emgality (galcanezumab) have been evaluated in post-hoc analyses of women with menstrual migraine history, but none has pursued a dedicated regulatory indication. The LUNA trial's prospective, indication-specific design positions atogepant differently from those agents in this setting. AbbVie said it plans to submit the LUNA data to health authorities globally and present full results at a future medical congress. The specific dose used in LUNA was not disclosed in the topline release. Access the AllSci platform to explore the science behind the news. Spot something wrong? Report an issue with this article

Phase 3Clinical ResultDrug Approval

17 Jun 2026

·firstwordpharma.com

Vedana debuts with $46M and a team of veterans to become 'the migraine company'

While the approval of the first CGRP inhibitor in 2018 was a watershed moment for the migraine disease space, too many patients still have too many migraines, Vedana Therapeutics CEO Anurag Agarwal told FirstWord. The biotech, which launched on Wednesday with $46 million in series A funding, is led by experts who helped usher in the first migraine revolution — but recognise that more work is needed. CGRP inhibitors "were the first specialised treatments designed for migraine patients," Agarwal said. "However, two-thirds of patients don't have sufficient benefits, they don't have deep reductions in migraine days" after trying therapies like Amgen's Aimovig (erenumab-aooe) or Teva's Ajovy (fremanezumab-vfrm). To help non-responders get migraine relief, Vedana is developing antibodies that inhibit a wholly independent pathway involving pituitary adenylate cyclase-activating polypeptide (PACAP). "PACAPs, like CGRPs, have been shown that when you infuse it in migraine patients, it induces migraine-like headaches. But unlike CGRPs, it induced a much broader symptomology of migraine… [like] facial puffing, neck stiffness," Agarwal said. In early studies, even with complete CGRP blockade, the infusion of PACAPs still drove migraines, demonstrating that it is a "complementary pathway that could address what is not being addressed by CGRPs today," he added. The company's two lead programmes are a next-generation anti-PACAP mAb and a dual-targeting PACAP/CGRP bispecific antibody. With Wednesday's funding, co-led by Westlake BioPartners and Canaan Partners, Vedana hopes to move both into the clinic next year.Migraine competitionThe biotech is not alone in its pursuit of PACAP inhibition, however. Lundbeck looks to be the most advanced with bocunebart, a PACAP-targeting mAb that recently met the primary endpoint of a Phase IIb migraine study, though several others, including newly public Mentari Therapeutics and Slate Medicines, have preclinical PACAP assets. Despite the rapidly forming PACAP competition, Agarwal isn't worried, noting that CGRP development was also a crowded field. He also called the early success of Lundbeck's programme "wonderful" for patients. How Vedana will stand out, he said, is with best-in-class treatments that are more potent, long-acting, and can be delivered subcutaneously in a patient's home with an autoinjector. "Our goal is to be able to give medicines that are easily delivered to a large number of patients," Agarwal added.Lending Vedana a hand in meeting that goal is its team of experienced migraine scientists. Leon Garcia, the company's other co-founder and chief scientist, previously led the discovery and development of both anti-CGRP and -PACAP antibodies at Alder BioPharmaceuticals, which was acquired by Lundbeck in 2019 for close to $2 billion. Chief Medical Officer Ernesto Aycardi steered the pivotal and post-marketing studies for Ajovy, and Rob Lenz, executive chairman of the board, helmed Aimovig's development in his past role as Amgen's head of global development. "We have that unique experience of discovering, developing and bringing to patients migraine therapies. We have a team that has done that from the early to the late stages. So I think that we are in a very unique position to lead the field," Aycardi told FirstWord. "This company in the future is going to be the migraine company."

Phase 2AcquisitionDrug ApprovalClinical Result

17 Jun 2026

·allsci.com

Vedana launches with USD 46m via Series A to challenge CGRP monopoly in migraine prevention

Seattle-based Vedana Therapeutics has launched from stealth with a USD 46 million Series A financing round to advance a portfolio of antibody-based therapies targeting clinically validated pathways for migraine prevention. The round was co-led by Westlake BioPartners and Canaan Partners, with participation from Dawn Biopharma and Alexandria Venture Investments. Vedana’s pipeline centers on pituitary adenylate cyclase-activating polypeptide (PACAP) biology. Its lead program is a next-generation anti-PACAP antibody, and its second program is a bispecific antibody targeting both PACAP and calcitonin gene-related peptide (CGRP). PACAP is a neuropeptide that, like CGRP, plays a documented role in migraine physiology. Vedana’s antibodies are designed as long-acting, subcutaneously delivered agents intended for self-injection. CGRP-targeted antibodies — including erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality) — established the first generation of preventive migraine biologics and represented a meaningful clinical advance. However, the company and its investors contend that approximately two-thirds of patients remain inadequately controlled on existing therapies, creating a substantial opportunity for agents targeting complementary biology such as PACAP. Competitors in the emerging PACAP space include Lundbeck, which acquired Alder BioPharmaceuticals — the company where Vedana’s co-founder and chief scientific officer Leon Garcia, Ph.D., previously led anti-CGRP and anti-PACAP antibody discovery — and AbbVie, which has disclosed PACAP-targeting programs. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

AcquisitionIPOGene Therapy

100 Deals associated with Erenumab (Genetical Recombination)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10928	Erenumab (Genetical Recombination)	N02CD01	DB14039

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Migraine Disorders	United States	Amgen, Inc.	17 May 2018

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Trigeminal Nerve Diseases	Phase 2	United States	Amgen, Inc.	31 May 2022
Trigeminal Nerve Injuries	Phase 2	United States	Amgen, Inc.	31 May 2022
Temporomandibular Joint Disorders	Phase 2	United States	Amgen, Inc.	15 Nov 2021
Flushing	Phase 2	Denmark	Novartis Pharmaceuticals Corp.	09 Jun 2020
Rosacea	Phase 2	Denmark	Novartis Pharmaceuticals Corp.	09 Jun 2020
Neuralgia	Phase 2	Denmark	Novartis AG	09 Apr 2019
Trigeminal Neuralgia	Phase 2	Denmark	Novartis AG	09 Apr 2019
Headache	Phase 2	Denmark	Novartis AG	05 Apr 2019
Headache	Phase 2	Denmark	Amgen, Inc.	05 Apr 2019
Post-Concussion Syndrome	Phase 2	Denmark	Novartis AG	05 Apr 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03867201 (DRAGON, Pubmed \| J Headache Pain)	Phase 3	Migraine Disorders	226	Erenumab 70 mg (Chronic Migraine)	dfustndodt(cejxtgvsvl) = voyutyfako pwbbcdcqvr (umrbmkhkaj ) View more	Positive	17 Jun 2026
TEMPLE (AAN2026)	-	Migraine Disorders	248	Atogepant 60mg once daily	xyvlkdcvvp(acxefnfjes): Difference (Mean) = -0.69, P-Value = 0.18 View more	Positive	25 Apr 2026
				Erenumab 70mg or 140mg once monthly
AAN2026	Not Applicable	Migraine Disorders	17,220	Erenumab	rcrfvafjue(waohfznkga) = enudtlovpu dlolnfoyuq (xutgamkvkz, 0.96 - 1.21) View more	Positive	25 Apr 2026
				Fremanezumab	rancskyqne(rnfupxjdrm) = gggajtcvym kdxixsnkia (enfqnoidjf ) View more
NCT04603976 (REFORM, Pubmed \| Eur J Neurol)	Phase 4	Migraine Disorders	582	Erenumab 140 mg	fqqrsjaeoa(tbxlmxkzqp) = For HIT-6, optimal thresholds included an 8-point reduction (53% sensitivity, 84% specificity) or a 12% relative reduction (54% sensitivity, 84% specificity). umsqcogasg (ogpvblyrei ) View more	Negative	01 Apr 2026
NCT03333109 (EMPOwER, Pubmed \| Neurol Clin Pract)	Phase 3	Migraine Disorders	900	Erenumab 140 mg	znnpnqxskj(ojsuywzoxr) = exacrsmatl syvfdmosup (fdxgddliju ) View more	Positive	01 Apr 2026
				Erenumab 70 mg	znnpnqxskj(ojsuywzoxr) = vyhsepgbpg syvfdmosup (fdxgddliju ) View more
NCT04252742 (EMBRACE, Pubmed \| Headache)	Phase 4	-	510	Erenumab 140 mg	pkgbtexyqf(nwbccpynno) = Compared with placebo, erenumab significantly reduced migraine functional impact as assessed by the four domains of the Migraine Functional Impact Questionnaire, with a least squares mean (95% CI) difference of −7.36 (−10.80, −3.92) for physical functioning, −7.10 (−10.34, −3.87) for usual activities, −6.82 (−10.37, −3.27) for social functioning, and − 7.05 (−10.76, −3.34) for emotional functioning ( p < 0.001 for all domains). dxrsbnnfzm (hbkupofrcs )	Positive	01 Mar 2026
				Placebo
NCT04098250 (CTgov)	Phase 2	Post-Traumatic Headache	6	Erenumab (Erenumab)	hvifbaeyhh(pvdrhkwiky) = iuxfoejiay cncighsqsg (hnukszfulv, 2.8) View more	-	23 Oct 2025
				Placebo (Placebo)	hvifbaeyhh(pvdrhkwiky) = rkywwgpode cncighsqsg (hnukszfulv, 6.0) View more
NCT04884763 (CTgov)	Phase 2	Temporomandibular Joint Disorders	30	Erenumab-aooe (Arm A)	oudeoclseo(wbwwtclnlo) = tfhuzdlbim enojtsiand (xzmdpedazk, bvkumabzai - evzodsuoae) View more	-	19 Aug 2025
				Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments (Arm B)	oudeoclseo(wbwwtclnlo) = orepurpcji enojtsiand (xzmdpedazk, izccwcpdbe - nsmrrgcjrk) View more
NCT03971071 (Pubmed \| Eur J Neurol)	Phase 4	Headache Disorders, Secondary	552	Erenumab 70 mg	jemyflomjr(gyemwxfazf) = No new safety concerns were identified (grade ≥ 3, 35 [6.3%]; serious, 17 [3.1%]; adverse events leading to treatment discontinuation, 5 [0.9%]) apgazwvhsn (hwjyiuklua )	Positive	01 Aug 2025
				Erenumab 140 mg
NCT04970355 (CHERUB01, Pubmed \| JAMA Netw Open)	Phase 2	Cluster Headache CGRP	81	Erenumab	cdulqvlkpw(scaszjnwjc) = oatsfhkuwh fmojyjgdib (sgdnckswog )	Negative	17 Jun 2025
				Placebo	cdulqvlkpw(scaszjnwjc) = pabyaybxyn fmojyjgdib (sgdnckswog )

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.